PDL-GEX

N/A

Report date: 2025/01/26 17:44:29

Base Information

Drug NamePDL-GEX
Drug Alias Namedual PD-L1 checkpoint inhibitor/CD16a activator (Glycotope)dual PD-L1 checkpoint inhibitor/FcgRIIIa activator (Glycotope)PDL-GEX
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionProgrammed death-ligand 1 blockersLow affinity immunoglobulin gamma Fc region receptor III-A agonists
TargetsProgrammed death-ligand 1Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlycotope Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesGlycotope Gmbh
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A